Related references
Note: Only part of the references are listed.Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6
Rongya Tao et al.
JOURNAL OF LIPID RESEARCH (2013)
Regulation of cholesterol homeostasis
Mariette Y. M. van der Wulp et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters
Minhao Wu et al.
ATHEROSCLEROSIS (2012)
The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells
Hai Li et al.
BIOCHEMICAL JOURNAL (2012)
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Maxime Denis et al.
CIRCULATION (2012)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
LDL cholesterol targets - how low to go?
Richard Bulbulia et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Proprotein convertase subtilisin/kexin type 9 inhibition
David A. Marais et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Hepatic Suppression of Foxo1 and Foxo3 Causes Hypoglycemia and Hyperlipidemia in Mice
Kebin Zhang et al.
ENDOCRINOLOGY (2012)
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
David Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Peroxisome Proliferator-activated Receptor γ Activation by Ligands and Dephosphorylation Induces Proprotein Convertase Subtilisin Kexin Type 9 and Low Density Lipoprotein Receptor Expression
Yajun Duan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
Ding Ai et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
The PCSK9 decade
Gilles Lambert et al.
JOURNAL OF LIPID RESEARCH (2012)
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins
Clapton S. Dias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J. Koren et al.
LANCET (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano et al.
LANCET (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
The Deacetylase Sirt6 Activates the Acetyltransferase GCN5 and Suppresses Hepatic Gluconeogenesis
John E. Dominy et al.
MOLECULAR CELL (2012)
The sirtuin SIRT6 regulates lifespan in male mice
Yariv Kanfi et al.
NATURE (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hepatic FoxOs Regulate Lipid Metabolism via Modulation of Expression of the Nicotinamide Phosphoribosyltransferase Gene
Rongya Tao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells
Aiqin Cao et al.
JOURNAL OF LIPID RESEARCH (2011)
Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data
Mette Soerensen et al.
AGING CELL (2010)
SIRT6 protects against pathological damage caused by diet-induced obesity
Yariv Kanfi et al.
AGING CELL (2010)
Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
Lena Persson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Hepatic-Specific Disruption of SIRT6 in Mice Results in Fatty Liver Formation Due to Enhanced Glycolysis and Triglyceride Synthesis
Hyun-Seok Kim et al.
CELL METABOLISM (2010)
Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
Jeffrey D. Browning et al.
JOURNAL OF LIPID RESEARCH (2010)
Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
Bin Dong et al.
JOURNAL OF LIPID RESEARCH (2010)
SIRT6 Links Histone H3 Lysine 9 Deacetylation to NF-κB-Dependent Gene Expression and Organismal Life Span
Tiara L. A. Kawahara et al.
CELL (2009)
Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6
Eriko Michishita et al.
CELL CYCLE (2009)
The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability
Bo Yang et al.
CELL CYCLE (2009)
Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors
Lena Persson et al.
ENDOCRINOLOGY (2009)
Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
Hai Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
Yi Luo et al.
JOURNAL OF LIPID RESEARCH (2009)
Association of FOXO3A variation with human longevity confirmed in German centenarians
Friederike Flachsbart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Association of the FOXO3A Locus with Extreme Longevity in a Southern Italian Centenarian Study
Chiara Viviani Anselmi et al.
REJUVENATION RESEARCH (2009)
Diabetes alters LDL receptor and PCSK9 expression in rat liver
Melissa Niesen et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Berberine decreases PCSK9 expression in HepG2 cells
Jamie Cameron et al.
ATHEROSCLEROSIS (2008)
Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
Robert J. Schmidt et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation
Xiaocheng C. Dong et al.
CELL METABOLISM (2008)
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Cedric Langhi et al.
FEBS LETTERS (2008)
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9
Sanae Kourimate et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin
Eriko Michishita et al.
NATURE (2008)
FOXO-binding partners: it takes two to tango
K. E. van der Vos et al.
ONCOGENE (2008)
FOXO3A genotype is strongly associated with human longevity
Bradley J. Wilicox et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2
Hyun Jeong Jeong et al.
JOURNAL OF LIPID RESEARCH (2008)
FoxO3 coordinately activates protein degradation by the Autophagic/Lysosomal and proteasomal pathways in atrophying muscle cells
Jinghui Zhao et al.
CELL METABOLISM (2007)
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis
Ji-Hye Paik et al.
CELL (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
FoxO1 regulates multiple metabolic pathways in the liver - Effects on gluconeogenic, glycolytic, and lipogenic gene expression
WW Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6
R Mostoslavsky et al.
CELL (2006)
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
F Lalanne et al.
JOURNAL OF LIPID RESEARCH (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice
KN Maxwell et al.
JOURNAL OF LIPID RESEARCH (2003)
Share Paper
